Targeting protein tyrosine phosphatase non-receptor type 2 with a novel inhibitor for AML therapy
Kuang, W.; Jiang, J.; Wang, X.; Wang, D.; Ji, M.; Zhu, Y.; Yuan, K.; Ding, J.; Wang, W.; Song, M.; Min, W.; Huang, F.; Wang, L.; Gu, W.; Hao, H.; Xiao, Y.; Yang, P.
Show abstract
Acute myeloid leukemia (AML) is a fatal disease characterized by a bleak prognosis. For over four decades, treatment options for AML have been constrained to administering high-dose cytotoxic chemotherapy. However, the emergence of drug resistance and the resultant toxic side effects have created an urgent necessity for identifying novel therapeutic targets. In this study, non-receptor protein tyrosine phosphatase type 2 (PTPN2) is highly expressed in AML. Remarkably, knock down of PTPN2 expression markedly mitigated AML burden both in vitro and in vivo. Additionally, we unveiled the direct interaction between PTPN2 and C-MYC, establishing C-MYC as a direct acting substrate of PTPN2. Then, we performed a small-molecule compound screening to identify K73, a selective inhibitor of PTPN2. At the same time, K73 showed a good safety profile and exhibited strong activity against AML in vivo. In conclusion, we have pinpointed a considerable therapeutic potential in targeting PTPN2 for AML treatment and discovered a novel class of selective PTPN2 inhibitors suitable for AML therapy.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Activating SRC/MAPK signaling via 5-HT1A receptor contributes to the effect of vilazodone on improving thrombocytopenia 95%
- STAMBPL1 activates the GRHL3/HIF1A/VEGFA axis through interaction with FOXO1 to promote angiogenesis in triple-negative breast cancer 95%
- Discovery and biological evaluation of a potent small molecule CRM1 inhibitor for its selective ablation of extranodal NK/T cell lymphoma 94%
Similar papers in this journal
- SARS-CoV-2-Triggered Mast Cell Rapid Degranulation Induces Alveolar Epithelial Inflammation and Lung Injury 94%
- ACE2-Targeting Monoclonal Antibody as Potent and Broad-Spectrum Coronavirus Blocker 92%
- Epigenetic reader ZMYND11 noncanonical function restricts HNRNPA1-mediated stress granule formation and oncogenic activity 92%
Similar papers in this journal
- Selective targeting of an oncogenic KRAS mutant allele by CRISPR/Cas9 induces efficient tumor regression 94%
- Metabolic remodeling by TIGAR overexpression is a therapeutic target in esophageal squamous-cell carcinoma 93%
- Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition 93%